Ocular Therapeutix Inc
NASDAQ:OCUL
Ocular Therapeutix Inc
Net Income (Common)
Ocular Therapeutix Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
Net Income (Common)
-$115.3m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-21%
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income (Common)
$38.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income (Common)
-$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Net Income (Common)
-$309m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income (Common)
$2.3B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income (Common)
$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
See Also
What is Ocular Therapeutix Inc's Net Income (Common)?
Net Income (Common)
-115.3m
USD
Based on the financial report for Mar 31, 2024, Ocular Therapeutix Inc's Net Income (Common) amounts to -115.3m USD.
What is Ocular Therapeutix Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-21%
Over the last year, the Net Income (Common) growth was -30%. The average annual Net Income (Common) growth rates for Ocular Therapeutix Inc have been 4% over the past three years , -13% over the past five years , and -21% over the past ten years .